US › Healthcare

Protara Therapeutics Inc (TARA)

US · Healthcare · Biotechnology

$4.01+1.01%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-17.8M
Profit YoY
-49.3%
EPS
$-0.31
EPS estimate
$-0.37

EPS came in at -0.31 against a street estimate of -0.37 — a beat of 16.2%.

Key statistics

Market cap
$220.3M
Forward P/E
0.0
P/B
1.22
Book value
$3.29
EPS (TTM)
$-1.36
52-week high
$7.82
52-week low
$2.97
50-day MA
$4.17
200-day MA
$5.28
Beta
1.48

Analyst view

Analysts rate Protara Therapeutics Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $26.57.

Shareholding

Insiders
2.42%
Institutions
81.06%

Largest institutional holders

FundStake
HHG PLC9.46%
BlackRock Inc6.17%
Velan Capital Investment Management LP5.15%
Millennium Management LLC5.14%
Blackstone Inc4.11%
Vanguard Capital Management, LLC3.85%
Sio Capital Management, LLC3.58%
Integral Health Asset Management, LLC3.18%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Protara Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.